PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22388934-7	2012	In both hypoxia and monocrotaline-induced PAH rat models, which display reduced levels of bmpr2 transcripts, this study further indicates that the TGFbeta-MAPK axis is activated in lungs following elevation of both expression and phosphorylation of the TAK1 protein.	Monocrotaline	20-33	bone morphogenetic protein receptor type 2	Rattus norvegicus	90-95	
30977250-5	2019	METHODS: We assessed the therapeutic effect of intravenously injected BMPR2-augmented rat bone marrow-derived endothelial-like progenitor cells (BMPR2-BM-ELPC) on PAH in the rat monocrotaline (MCT) model.	Monocrotaline	178-191	bone morphogenetic protein receptor type 2	Rattus norvegicus	70-75	
21619414-0	2011	Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats.	Monocrotaline	68-81	bone morphogenetic protein receptor type 2	Rattus norvegicus	15-20	
21619414-2	2011	The present study was designed to investigate the involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline (MCT)-induced endothelial apoptosis in rats.	Monocrotaline	118-131	bone morphogenetic protein receptor type 2	Rattus norvegicus	65-70	
21619414-2	2011	The present study was designed to investigate the involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline (MCT)-induced endothelial apoptosis in rats.	Monocrotaline	133-136	bone morphogenetic protein receptor type 2	Rattus norvegicus	65-70	
21619414-8	2011	These findings suggest that BMPR2 is probably involved in the protective effect of fluoxetine against MCT-induced endothelial apoptosis in rats.	Monocrotaline	102-105	bone morphogenetic protein receptor type 2	Rattus norvegicus	28-33	
34347342-7	2021	In line with PAH status, pulmonary microvessels in monocrotaline-treated animals demonstrated significant (p<0.05, n=6 per group) upregulation of alphaSMA (two fold) and downregulation of BMPR2 (20%).	Monocrotaline	51-64	bone morphogenetic protein receptor type 2	Rattus norvegicus	188-193	
34347342-10	2021	MQCM and Western blot analysis showed that monocrotaline-induced ZIP12 upregulation could be partially negated by BMPR2-targeted therapy.	Monocrotaline	43-56	bone morphogenetic protein receptor type 2	Rattus norvegicus	114-119	
34347342-11	2021	Our results indicate that altered zinc transport/storage and S1P signalling in the monocrotaline-induced PAH rat model are linked to each other, and could be alleviated by BMPR2-targeted therapy.	Monocrotaline	83-96	bone morphogenetic protein receptor type 2	Rattus norvegicus	172-177	
18367643-8	2008	There was a decrease in the expression of the full BMPrII protein but not its short form variant in MCT-treated rat lungs.	Monocrotaline	100-103	bone morphogenetic protein receptor type 2	Rattus norvegicus	51-57	
35395852-4	2022	METHODS: A monoallelic single nucleotide insertion in exon 1 of Bmpr2 (+/44insG) was generated in rats using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9, then PH, pulmonary vascular disease (PVD) and survival after MCT injection with or without a phosphodiesterase type 5 inhibitor, tadalafil, administration were assessed.	Monocrotaline	266-269	bone morphogenetic protein receptor type 2	Rattus norvegicus	64-69	
35395852-12	2022	CONCLUSIONS: The present study demonstrates that the Bmpr2 mutation promotes dedifferentiation of PA smooth muscle cells, late PVD and RV myocardial fibrosis and adversely impacts both the natural and post-treatment courses of MCT-PH in rats with significant effects only in the late stages and warrants preclinical studies using this new genetic model to optimize treatment outcomes of heritable PAH.	Monocrotaline	227-230	bone morphogenetic protein receptor type 2	Rattus norvegicus	53-58	
30977250-5	2019	METHODS: We assessed the therapeutic effect of intravenously injected BMPR2-augmented rat bone marrow-derived endothelial-like progenitor cells (BMPR2-BM-ELPC) on PAH in the rat monocrotaline (MCT) model.	Monocrotaline	178-191	bone morphogenetic protein receptor type 2	Rattus norvegicus	145-150	
30977250-5	2019	METHODS: We assessed the therapeutic effect of intravenously injected BMPR2-augmented rat bone marrow-derived endothelial-like progenitor cells (BMPR2-BM-ELPC) on PAH in the rat monocrotaline (MCT) model.	Monocrotaline	193-196	bone morphogenetic protein receptor type 2	Rattus norvegicus	70-75